Becton, Dickinson and Company (NYSE:BDX) Receives $195.46 Average Target Price from Analysts

Shares of Becton, Dickinson and Company (NYSE:BDX) have been given a consensus rating of “Hold” by the sixteen analysts that are covering the stock, MarketBeat reports. One analyst has rated the stock with a sell rating, ten have issued a hold rating and five have assigned a buy rating to the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $195.4615.

A number of brokerages recently commented on BDX. Stifel Nicolaus lifted their price objective on Becton, Dickinson and Company from $210.00 to $215.00 and gave the stock a “buy” rating in a research note on Wednesday, January 7th. TD Cowen increased their target price on Becton, Dickinson and Company from $183.00 to $189.00 and gave the company a “hold” rating in a research note on Wednesday, February 11th. Royal Bank Of Canada set a $172.00 target price on Becton, Dickinson and Company in a research report on Tuesday, February 10th. Jefferies Financial Group lowered their price target on Becton, Dickinson and Company from $220.00 to $190.00 and set a “buy” rating for the company in a research note on Tuesday, February 10th. Finally, Zacks Research cut shares of Becton, Dickinson and Company from a “hold” rating to a “strong sell” rating in a report on Wednesday, February 11th.

Becton, Dickinson and Company Trading Down 0.4%

BDX opened at $163.22 on Monday. The firm has a 50 day simple moving average of $191.41 and a 200 day simple moving average of $190.50. Becton, Dickinson and Company has a fifty-two week low of $127.59 and a fifty-two week high of $187.35. The company has a market cap of $46.47 billion, a price-to-earnings ratio of 26.63, a price-to-earnings-growth ratio of 11.88 and a beta of 0.24. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.05 and a quick ratio of 0.58.

Becton, Dickinson and Company (NYSE:BDX) last released its earnings results on Monday, February 9th. The medical instruments supplier reported $2.91 EPS for the quarter, topping analysts’ consensus estimates of $2.81 by $0.10. The firm had revenue of $5.25 billion during the quarter, compared to analyst estimates of $5.15 billion. Becton, Dickinson and Company had a net margin of 8.01% and a return on equity of 15.76%. The business’s quarterly revenue was up 1.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned $3.43 EPS. Becton, Dickinson and Company has set its FY 2026 guidance at 12.350-12.650 EPS. On average, sell-side analysts anticipate that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Becton, Dickinson and Company declared that its Board of Directors has initiated a stock repurchase plan on Tuesday, January 27th that permits the company to repurchase $10.00 million in shares. This repurchase authorization permits the medical instruments supplier to buy up to 0% of its shares through open market purchases. Shares repurchase plans are often a sign that the company’s leadership believes its shares are undervalued.

Becton, Dickinson and Company Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 31st. Stockholders of record on Tuesday, March 10th will be given a dividend of $1.05 per share. This represents a $4.20 dividend on an annualized basis and a dividend yield of 2.6%. The ex-dividend date of this dividend is Tuesday, March 10th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is currently 68.52%.

Insiders Place Their Bets

In other Becton, Dickinson and Company news, Director Bertram L. Scott sold 953 shares of the business’s stock in a transaction dated Wednesday, February 18th. The stock was sold at an average price of $182.61, for a total value of $174,027.33. Following the completion of the transaction, the director directly owned 36,763 shares of the company’s stock, valued at approximately $6,713,291.43. The trade was a 2.53% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Michael David Garrison sold 1,610 shares of the stock in a transaction dated Thursday, January 15th. The stock was sold at an average price of $207.46, for a total value of $334,010.60. Following the completion of the sale, the executive vice president owned 12,095 shares of the company’s stock, valued at $2,509,228.70. This trade represents a 11.75% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 3,416 shares of company stock valued at $674,693. 0.40% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Becton, Dickinson and Company

Institutional investors and hedge funds have recently modified their holdings of the business. Larry Mathis Financial Planning LLC bought a new position in Becton, Dickinson and Company in the fourth quarter valued at approximately $281,000. Auto Owners Insurance Co increased its position in shares of Becton, Dickinson and Company by 22,225.2% during the fourth quarter. Auto Owners Insurance Co now owns 40,711,035 shares of the medical instruments supplier’s stock worth $790,079,000 after acquiring an additional 40,528,680 shares in the last quarter. Union Savings Bank acquired a new stake in shares of Becton, Dickinson and Company during the fourth quarter worth $76,000. Hsbc Holdings PLC lifted its position in Becton, Dickinson and Company by 53.7% in the 4th quarter. Hsbc Holdings PLC now owns 940,908 shares of the medical instruments supplier’s stock valued at $183,161,000 after acquiring an additional 328,717 shares in the last quarter. Finally, Gunpowder Capital Management LLC dba Oliver Wealth Management acquired a new position in Becton, Dickinson and Company in the 4th quarter worth $112,000. 86.97% of the stock is currently owned by institutional investors and hedge funds.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.